Nicola Normanno
Yahoo!
CancerInternal medicinePathologyOncologyMolecular biologyLung cancerEpidermal growth factorChemotherapyCriptoEpidermal growth factor receptorCetuximabGefitinibKRASEgfr mutationCancer researchColorectal cancerBreast cancerClinical trialMedicineBiology
375Publications
74H-index
16.7kCitations
Publications 386
Newest
#1Ignacio Melero (University of Navarra)H-Index: 81
#2Nicola NormannoH-Index: 74
Source
#1Mauro PiccirilloH-Index: 14
#2Laura BonannoH-Index: 19
Last. Laura ArenareH-Index: 8
view all 20 authors...
Source
Source
Abstract null null The personalized medicine is in a rapidly evolving scenario. The identification of actionable mutations is revolutionizing the therapeutic landscape of tumors. The morphological and histological tumor features are enriched by the extensive genomic profiling, and the first tumor-agnostic drugs have been approved regardless of tumor histology, guided by predictive and druggable genetic alterations. This new paradigm of “mutational oncology”, presents a great potential to change ...
13 CitationsSource
#1Priscilla CascettaH-Index: 3
#2Vincenzo SforzaH-Index: 12
Last. Rossella De CecioH-Index: 10
view all 18 authors...
RET rearrangements are observed in 1–2% of non-small-cell lung cancer (NSCLC) patients and result in the constitutive activation of downstream pathways normally implied in cell proliferation, growth, differentiation and survival. In NSCLC patients, RET rearrangements have been associated with a history of non-smoking, a higher rate of brain metastasis at initial diagnosis and a low immune infiltrate. Traditionally, RET fusions are considered mutually exclusive with other oncogenic drivers, even ...
Source
Source
#1Erika Martinelli (Seconda Università degli Studi di Napoli)H-Index: 41
#2Giulia Martini (Seconda Università degli Studi di Napoli)H-Index: 14
Last. Pietro Paolo Vitiello (Seconda Università degli Studi di Napoli)H-Index: 7
view all 30 authors...
Importance null Rechallenge therapy with anti-epidermal growth factor receptor (EGFR) drugs has been suggested in patients with chemo-refractory RAS wild-type (WT) metastatic colorectal cancer (mCRC) after initial response to anti-EGFR-based first-line treatment. The association of treatment with cetuximab plus avelumab with overall survival (OS) may be worthy of investigation in this setting. null Objective null To assess the efficacy and safety of cetuximab rechallenge therapy plus avelumab. n...
Source
#1Parth Shah (Dartmouth College)
#2Jacob Sands (Harvard University)H-Index: 6
Last. Nicola NormannoH-Index: 74
view all 3 authors...
Epidermal growth factor receptor (EGFR) mutation testing in advanced non-small-cell lung cancer (NSCLC) has evolved rapidly over the past decade, largely triggered by the introduction of the targeted EGFR tyrosine kinase inhibitors (TKIs). Initially used to detect common EGFR mutations and determine the most appropriate first-line therapy at diagnosis, testing methodologies have expanded to test for multiple mutations at multiple time points throughout the disease course. Here we review the curr...
Source
#1Carmine Pinto (AUSL: Academy for Urban School Leadership)H-Index: 31
#2Mauro Biffoni (ISS: Istituto Superiore di Sanità)H-Index: 37
Last. Nicola NormannoH-Index: 74
view all 7 authors...
Next-generation sequencing (NGS) and liquid biopsy are new technologies that can allow overall tumor profiling in a single analysis and play an important role in the implementation of precision oncology. However, the lack of guidelines in this setting has limited the development of precision oncology in Italy. This article summarizes recommendations for the appropriate use of NGS in tumor gene profiling, as well as access to tests and target drugs, that were prepared by a group of key opinion le...
1 CitationsSource
Tumor mutation burden (TMB) is evaluated as a biomarker of response to immunotherapy. We present the efforts of the Onconetwork Immuno-Oncology Consortium to validate a commercial targeted sequencing test for TMB calculation. A three-phase study was designed to validate the Oncomine Tumor Mutational Load (OTML) assay at nine European laboratories. Phase 1 evaluated reproducibility and accuracy on seven control samples. In phase 2, six formalin-fixed, paraffin-embedded samples tested with Foundat...
Source